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Abstract: Breast cancer is a disease of a specific organ, but its effects are felt throughout the
body. The systemic effects of breast cancer can lead to functional limitations in patients who suffer
from muscle weakness, fatigue, pain, fibromyalgia, or many other dysfunctions, which hasten
cancer-associated death. Mechanistic studies have identified quite a few molecular defects in skeletal
muscles that are associated with functional limitations in breast cancer. These include circulating
cytokines such as TNF-α, IL-1, IL-6, and TGF-β altering the levels or function of myogenic molecules
including PAX7, MyoD, and microRNAs through transcriptional regulators such as NF-κB, STAT3,
and SMADs. Molecular defects in breast cancer may also include reduced muscle mitochondrial
content and increased extracellular matrix deposition leading to energy imbalance and skeletal muscle
fibrosis. This review highlights recent evidence that breast cancer-associated molecular defects
mechanistically contribute to functional limitations and further provides insights into therapeutic
interventions in managing functional limitations, which in turn may help to improve quality of life in
breast cancer patients.
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1. Prevalence of Functional Limitations in Breast Cancer
Breast cancer is one of the most common malignancies affecting one in eight women in the
United States. With disease progression, breast cancer causes dramatic systemic effects. Myopenia
and cachexia under metastatic settings are observed in ~25% of breast cancer patients, particularly
in women with triple-negative breast cancer [1,2]. Functional limitations are observed even before
cancer diagnosis and are the major reasons for increased no-cancer related deaths in these patients [3,4].
In a recent study, a cohort of 2202 women with breast cancer was examined and approximately
40% breast cancer patients demonstrated at least one of the functional limitations [5]. Patients with
functional limitations exhibit decreased volitional activity, whole body weakness, and fatigue [6–10].
The prevalence of functional limitations in breast cancer patients is dependent on disease stage, age,
ethnicity, demographics, and physical compositions [5]. Indeed, functional limitations are more
common among older breast cancer patients [5,11]. Women with functional limitations are more likely
to be overweight or obese with less physically activity [5,12]. More critically, preclinical and clinical
data demonstrate that functional limitations result in significantly shorter survival due to non-cancer
causes of death [5,13].
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2. Functional Limitation is Likely Due to Skeletal Muscle Dysfunction in Breast Cancer
Growing evidence points to skeletal muscle dysfunction as a major cause of cancer-associated
functional limitations. Skeletal muscles represent 40%–50% of the total body mass of a healthy human,
making them collectively one of the largest organ systems [14,15]. A defining characteristic of skeletal
muscles is its remarkable capacity of generating power for motion of an individual to maintain
activities and to ensure the quality of life [16,17]. Thus, muscle force production, fatigue, and twitch
characteristics are functional properties that define skeletal muscle quality. Life quality change
associated with aging, Duchenne muscular dystrophy (DMD), chronic obstructive pulmonary disease
(COPD), and cancer is directly related to these muscle parameters [18–22]. Recently, specific decrements
to skeletal muscle’s contractile quality have been identified in cachectic patients and tumor-bearing
mice. Women with breast cancer are found to have reduced cross-sectional areas of a single muscle fiber
compared with cancer-free controls. In addition, women with breast cancer have reduced fractional
content of both subsarcolemmal and intermyofibrillar mitochondria [23]. This observation is consistent
with a higher risk of dying due to low levels of muscle mass in women with breast cancer compared
to women who have adequate muscle mass [24]. Furthermore, women with higher muscle mass
demonstrate improved response to cancer treatment and overall survival [25,26]. Preclinical data from
animal models of breast cancer demonstrated that mice with primary mammary tumors have reduced
grip strength and declined motor activity [13]. In line with functional limitations, reduction of body fat
and increased body free water were observed in the transgenic PyMT mouse model, which represents
the luminal B subtype of human breast cancer. Tumor progression also caused decrement of grip
strength and reduction of specific force generated by muscle contraction [27], which might be related to
the decreased size of muscle fibers and muscle mitochondria [23]. Moreover, breast cancer-associated
functional limitations, including muscle weakness and reduced muscle force, correlate with dynamic
systemic changes in cytokine/chemokine levels and myogenic regulation (Figure 1). This process
involves complex gene expression regulatory networks in the skeletal muscle differentiation hierarchy,
which is influenced by the chemokines and cytokines (Figure 1). In breast cancer bone metastasis
models, body weight loss is associated with skeletal muscle atrophy and specific changes in the activity
of skeletal muscle ryanodine receptors and the calcium (Ca2+) release channel [27].
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the breast release growth factors and cytokines into the circulating system. In response to tumors, host
immune cells in breast tissue and other organs also release growth factors and cytokines into circulation.
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These growth factors and cytokines activate NF-κB in tumors, which further enhance the expression
and release of growth factors and cytokines into circulation. Circulating growth factors and cytokines
such as TGF-β and TNF-α are transported into skeletal muscles where, through their selective receptors,
activate signaling molecules such as NF-κB in myogenic cells. Activated NF-κB regulates a series
of molecules through its downstream signaling, feedback regulations, and cross-talk interactions.
Tumor-induced reduction of Cox-IV, Prka-γ and Atp2a1 in skeletal muscles results in defective energetic
regulation leading to fatigue in breast cancer patients. miR-486 and miR-206 are expressed in the
mitochondria of myofibers, but their role in regulating energy remains unknown. Reduced expression
of Pax7, MyoD, Myf5/6, and MyoG in skeletal muscles impairs proliferation and differentiation of
MuSCs, which is exacerbated by downregulation of Bcl-2, miR-486, and miR-206. These actions
lead to myogenic defects such as reduced number and size of myofibers, which is associated with
myoatrophy. Downregulation of Mmp-9 and laminin A in skeletal muscles could contribute to increased
ECM deposition and myofibrosis. Decreased expression of muscle-specific miR-486 and miR-206
may contribute to their lower levels in circulation. Whether the neuromuscular junction is affected
by breast cancer is unknown. Furthermore, whether the tumor itself or cancer treatment affects the
gut microbiome, which then changes muscle function, is unknown. Overall, breast cancer-induced
impairment of myogenesis, energetic inefficiency, and ECM remodeling leads to functional limitations,
which may be manifested clinically as fatigue, muscle weakness, fibromyalgia with and without overt
cachexia. Pharmacological intervention through inhibitors of NF-κB such as DMAPT is a promising
therapeutic strategy.
3. Altered Cytokines Contribute to Functional Limitations in Breast Cancer
Cytokines are a large family of polypeptides and small proteins, including interleukin (e.g.,
IL-1, IL-2, IL-4), interferon (IFN-α, β, γ), chemokine, and tumor necrosis factor (TNF) families.
Cytokines produced by a variety of cell types exert their actions locally (autocrine and paracrine) or
systemically by directly interacting with their specific membrane receptors [28,29]. It has been well
established that cytokines secreted by host immune cells in response to tumors and/or by the tumor
itself are associated with muscle wasting and functional limitations [30,31]. High plasma levels of IL-6,
TNF-α, INF-γ, and IL-1β have been observed in both tumor-bearing animals and cachectic cancer
patients [32,33]. Fatigued women who survive breast cancer have significantly higher serum levels
of IL-1ra, sTNF-RII, and neopterin than non-fatigued women [34]. This cancer-associated increase in
pro-inflammatory activity is common across many diseases including autoimmune, inflammatory,
and infectious diseases [35–38]. In our preclinical models, we identified several cytokines/chemokines
secreted by mammary tumor lines derived from PyMT+ and Neu+ mice. Both cell lines secreted
Gm-csf, Tnf-α, Ccl-2, Ifn-γ, and IL-1α while Timp1 was uniquely secreted by the PyMT+ tumor line.
Neu+ mammary tumor line secreted G-csf, Ccl-1, Ccl-5, Cxcl-1, Cxcl-2, Cxcl-10, and Il-1ra. Recently,
we measured 33 circulating cytokines/chemokines in plasma of PyMT+ mice by using the Milliplex
kit and reported that Tnf-α, Tgf-α, β, G-csf, Il-6, and Gm-csf are elevated, whereas Mip-2 Cxcl-2,
Il-9, Cxcl-5, and Il-1α are decreased in tumor-bearing mice compared to age and sex-matched control
animals [13]. Thus, the cancer genome has an influence on the type of cytokines/chemokines secreted
by cancer cells and consequently on the type and severity of functional limitations. In addition, Peake
and colleagues [29] reported that skeletal muscle itself expresses a variety of cytokines, including
IFN-γ, TNF-α, LIF, TGF-β, and IL-6. Thus, cytokines produced locally and delivered systemically
act on muscles through their specific receptors on myogenic cells. Indeed, myogenic cells express
receptors that interact with cytokines including TNF-α, IL-1, IL-6, IFN-γ, and G-CSF [28,39,40].
Many cytokines have been well studied for their actions on cancer-associated muscle wasting
and functional limitations. TNF-α directly binds to type 1 TNF-α receptor (TNFR1) on muscle cells
resulting in increased reactive oxygen species production via mitochondrial electron transport and
activation of NF-κB signaling pathways. NF-κB increases the activity of the ubiquitin/proteasome
pathway, which accelerates the regulated degradation of muscle proteins and hence causes muscle
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weakness [41]. Indeed, our recent report showed that increased levels of Tnf-α, Tgf-β, and G-csf
in plasma of PyMT+ mice were accompanied by lower muscle mitochondrial activity and muscle
dysfunction, which were restored upon inhibition of NF-κB signaling pathways [13]. Interestingly,
TNF-α and several other cytokines have been shown to modulate peripheral insulin sensitivity with
a mechanism that affects the activation of the insulin receptor and downstream signaling molecules
in the skeletal muscles. In addition, TNF-α downregulated insulin-like growth factor-1-dependent
signaling pathways that reduced muscle anabolic capacity and enhanced pro-catabolic stimuli [32].
In animal models, treatment with Tgf-β results in muscle atrophy and fibrosis, which causes reduced
muscle contraction force [40,42]. In breast cancer with bone metastasis, Tgf-β causes muscle weakness
and reduces muscle contractibility [27,43]. Similarly, TGF-β and TNF-α enhance the expression of
zinc transporter ZIP14, which blocks the differentiation of muscle stem cells, also called satellite
cells (MuSCs), and enhances the loss of myosin heavy chain in the skeletal muscles [44]. Taken
together, breast cancer-associated alterations in circulating cytokines contribute to tumor-associated
muscle dysfunction (Figure 1). Cancer-specific genomic aberrations may determine the type of
cytokines/chemokines produced by cancer cells and pathways affected in the skeletal muscles.
4. Impaired Myogenesis Contributes to Functional Limitations in Breast Cancer
Healthy skeletal muscles have self-renewal capacity via MuSCs to replace injured or dead
myofibers [45,46]. Generally, MuSCs are located in niche reservoirs between muscle fibers and
extracellular matrix (ECM) and maintained in a quiescent state through activities of several factors
including MuSC-enriched transcription factor PAX7 [47,48]. When muscles are injured, MuSCs are
activated as myoblasts expressing both PAX7 and MyoD. Myoblasts have proliferating ability to
generate as many cells as needed to repair injury. While a portion of myoblasts expressing PAX7, but
lacking MyoD, return to quiescent state, the other major portion expressing MyoD, but lacking PAX7,
will go on to differentiate and form multinucleated myofibers, and finally replace injured muscle fibers
physically and functionally by expressing various contractile proteins, such as myosin heavy chain
(MyHC) and skeletal muscle alpha actin [47,49]. Tumors have a pronounced impact on the number of
regenerating myofibers in tumor-bearing mdx mice, a popular model to study DMD, compared to
the number of regenerating myofibers in tumor-free mdx mice [50]. Skeletal muscle in PDX mouse
cancer models also shows reduced regenerative capacity due to dysregulation of Pax7. Pax7 is of
importance during myogenesis at any age as Pax7 deficiency in mice results in cell cycle arrest and
precocious differentiation of MuSCs, which leads to impaired muscle regeneration [51,52]. As reported
previously, Pax7 not only contributes to MuSC activation and self-renewal but also regulates MuSC
proliferation and differentiation by acting on its target genes such as Myf5 and MyoD [53,54]. Indeed,
MyoD and Myf5 along with other myogenic regulatory factors Myf6 and MyoG, determine the
specification of myogenesis and influence MyHC levels and metabolic properties of myofibers [55].
In several of these models, through the P38 MAPK signaling pathway, TNF-α negatively regulates
Pax7 expression and contributes to impaired muscle regeneration [56]. In the PyMT+ mammary tumor
model, tumor-bearing mice contained lower skeletal muscle Pax7 as well as lower levels of MyoD along
with the upregulation of circulating Tnf-α [13]. As illustrated schematically in Figure 1, tumor-derived
cytokines/chemokines can impair specific steps of the myogenic program and contribute to functional
limitations [13].
In animals that lack inducible nitric oxide synthase (Nos2) expression, MuSCs fail to proliferate and
differentiate as a muscle damage-induced increase of Pax7+ MyoD+ double-positive cells is significantly
delayed in iNOS-deficient mice along with a significant decrease of MyoG compared to wild type
mice [57], indicating that Nos2 is required for effective regeneration of muscle. Nos2 is an enzyme that
regulates the synthesis of nitric oxide (NO), which is involved in adult skeletal muscle homeostasis,
particularly by mediating muscle regeneration after injury [58–61]. NO promotes activation, fusion,
and maintenance of the pool of MuSCs in acutely and chronically damaged muscles [62]. Skeletal
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muscle Nos2 expression in PyMT+ mammary tumor mice compared to wild type mice was significantly
lower [13], which may have an impact on recovery from injury.
Both BCL-2 and caspase-3 are key regulators of cell apoptosis [63,64]. BCL-2 prevents programmed
cell death by inhibiting shuttle proteins BAX and BAK, as enhanced activity of BAX and BAK leads
to caspase-3 activation that results in cell death [65,66]. In this regard, in human disease of DMD,
enhanced expression of caspase-3 is responsible for myofiber cell death and muscle atrophy [67].
However, a complex role of caspase 3 in skeletal muscle homeostasis is emerging [68]. Caspase 3
null mice compared to wild type mice have reduced muscle mass and myoblasts due to defects in
differentiation to myofibers with a parallel downregulation of MyoD and MyoG. These findings are
further confirmed in the C2C12 cell line by pharmacologically inhibiting caspase-3 activity. A recent
in vivo study showed that inhibition of caspase-3 activity results in a profound disruption in skeletal
muscle regeneration [69]. Taken together, caspase-3 is required for MuSC differentiation. With respect
to the role of Bcl-2 in myogenesis, Bcl-2+ C2C12 cells co-express markers of early stages of myogenesis,
including desmin, MyoD, and Myf-5, and expression of Bcl-2 promotes clonal expansion as the muscle
colonies produced by cloned Bcl-2–null cells contain only about half as many cells as the colonies
produced by cells with Bcl-2 [70]. Since cytokines such as TNF can influence the expression and/or
activity of Bcl-2 and caspase 3, circulating chemokine/cytokine-mediated changes in pro-apoptotic and
anti-apoptotic proteins in skeletal muscle could have a profound impact on skeletal muscle function in
cancer patients.
Skeletal muscle expresses many miRNAs [71–76] that regulate MuSC proliferation,
differentiation, and even muscle force production by modulating gene expression via transcriptional,
post-transcriptional, epigenetic mechanisms, and nuclear genome organization [71,77–80]. Cancer
affecting the expression of muscle-specific miRNAs has been reported recently in breast cancer [38],
rhabdomyosarcoma [81], pancreatic and colorectal cancer [82], gastric cancer [83], and lung cancer [84].
We reported that circulating levels of cardiac and skeletal muscle-enriched miR-486 were lower
in breast cancer patients with metastasis compared to healthy individuals [38]. In animal models
of breast cancer, lower circulating miR-486 levels correlate with reduced miR-486 expression in
skeletal muscle. Furthermore, proteins in the myogenesis (Pax7/MyoD/MyoG) and myofiber survival
(Dock3/Pten/Akt) networks, which are regulated by and/or regulate miR-486, are deregulated in skeletal
muscles of tumor-bearing transgenic mice compared to controls [38]. In mammary tumor-bearing
animals, the downregulation of miR-486 was correlated with the upregulation of circulating Tnf-α,
a cytokine that suppresses the expression of miR-486 in myoblasts in culture potentially via NF-κB
signaling pathways [13,38]. Thus, miR-486 is an integral part of the myogenesis signaling network
that involves Pax7, MyoD, myostatin, and NF-κB [15,85–87] and a potential target of cancer-induced
chemokines/cytokines. Reduced skeletal muscle miR-486 expression is a major defect in DMD and
transgenic expression of miR-486 in muscle could rescue muscular dystrophy phenotype in animal
models [88]. In this regard, based on our preclinical studies, we had previously proposed that loss of
miR-486 is responsible for functional limitations in breast cancer patients.
miR-206 is another one of the widely studied miRNAs in skeletal muscles [89]. miR-206 promotes
myoblast differentiation of C2C12 cells by blocking cell cycle progression and by inducing myofiber
formation [90] via its upstream regulator MyoD and downstream targets Pax7, Pax3, and estrogen
receptor-alpha [91]. During myoblast differentiation, MyoD activates miR-206 expression that, in turn,
downregulates Pax7 and Pax3 [92–94]. TGF-β and myostatin, which are upregulated in cancer patients,
downregulate miR-206 and MyoD levels in skeletal muscle. Skeletal muscles of myostatin knockout
mice compared to wild type mice have significantly higher levels of miR-206, while Tgf-β treatment
reduces the expression of miR-206 in C2C12 myoblasts [95,96]. Local injection of miR-206 into injured
skeletal muscles in rats enhanced muscle regeneration both morphologically and physiologically and
effectively inhibited muscle fibrosis [97]. These observations indicate the role of miR-206 in muscle
regeneration and muscle function. Thus, it is not surprising that elevated circulating Tgf-β in a PyMT+
mammary tumor model correlated with lower miR-206 in muscles and reduced muscle function
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(Figure 1) [13]. In addition, decreased circulating miR-206 is observed in breast cancer [98], renal cell
carcinoma [99], melanoma [100], and osteosarcoma [101] patients.
5. Energetic Inefficiency in Skeletal Muscle Contributes to Functional Limitations in Breast Cancer
Cachexia, myopenia, and functional limitations in cancer patients are generally associated
with a negative energy balance resulting from either reduced energy production or increased
energy expenditure during disease progression [102–104]. Advanced cancer patients have enhanced
thermogenesis that increases energy expenditure, which is consistent with the observation in cachectic
tumor-bearing animals [105]. It is also known that impairment of the mitochondrial compartment
results in decreased ATP production, leading to an energy deficit that becomes even worse since it is
coupled with steadily increased energy expenditure. Consistent with this possibility, we have shown
reduced muscle mitochondrial content in a PyMT+ mammary tumor model [13], and others have shown
reduced ATP levels and increased activity of the energy sensor AMPK [106,107], implying that breast
cancer decreases energy production in skeletal muscles. Thus, it is not surprising that skeletal muscles
of PyMT+ animals contained lower levels of Atp2a1 [13], an energy transfer enzyme that regulates
cellular calcium required for muscle contraction and muscle force production [108]. Interestingly,
miR-486 and miR-206 are localized in mitochondria [109], and it is known that miR-486 protects the
membrane potential of mitochondria to maintain cell integrity [110,111] through anti-apoptotic BCL-2
family proteins [112,113]. Thus, reduced miR-486 in skeletal muscles of tumor-bearing mice may
affect mitochondrial activity that regulates energy production. Collectively, current literature suggests
impaired energy production in skeletal muscle as a consequence of cancer, which may be responsible
for functional limitation (Figure 1).
6. Altered Extracellular Matrix Contributes to Functional Limitations in Breast Cancer
Extracellular matrix (ECM) consists of a variety of collagens, elastins, fibronectins, tenascins,
proteoglycans, and glycosaminoglycans [114]. ECM has dynamic influence on myofibers and muscle
function through ECM-directed remodeling events [115,116]. Metalloproteinases (MMPs) play
an essential role in ECM remodeling. MMP-2 and MMP-9 degrade collagen type IV of the basement
membranes, but also activate focal adhesion kinase that may lead to changes in integrin function
and modifications of the cytoskeleton [117]. During early disease stage of DMD, MMP-9, which is
elevated due to NF-kB activity, enhances myogenesis. However, during the later disease stage of
DMD, MMP-9 level is decreased, leading to the accumulation of fibroadipose tissues and reduced
muscle strength [118]. These findings indicate the dual actions of MMP-9 in ECM remodeling and
muscle regeneration. We reported that skeletal muscle of mammary tumor-bearing mice compared
to wild type mice had elevated ECM deposition, which could be due to a reduction of Mmp-9, [13].
The specific role of Mmp-9 in skeletal muscle remodeling is evident from transgenic and knockout
mouse models. Overexpression of Mmp-9 results in myofiber hypertrophy with increased fiber size
and contractile force [119]. On the other hand, knockout of the Mmp-9 gene causes muscle atrophy
by decreasing fiber cross-sectional areas and altering myofiber type distribution in mouse hindlimb
skeletal muscles [120]. Thus, enhanced ECM and decreased Mmp-9 in the skeletal muscle may directly
or indirectly contribute to muscle-associated functional limitations (Figure 1). Although MMP-9
has pro-tumorigenic and pro-metastatic roles, MMP-9 targeted therapies failed in clinical studies,
potentially due to its requirement for proper skeletal muscle function [121]. MMP members other
than MMP-9 could also play a role in skeletal muscle remodeling as the expression of laminin A,
a key component of basal membrane in muscle and an Mmp-11 target, which is downregulated
in muscles [122]. How cancer causes changes in skeletal muscle ECM is unknown but TGF-β is
the likely culprit as TGF-β is implicated in multiple fibrotic diseases [123–125]. TGF-β functions to
promote ECM preservation by enhancing collagen synthesis, expression of ECM and profibrotic genes,
and inhibiting ECM degradation [126,127] through reduced MMP activity [128–130]. Interestingly,
MMP-9 is a positive regulator of TGF-β as MMP-9 is required for the release of active TGF-β [131,132].
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Therefore, in cancer, it is likely that circulating TGF-β rather than locally produced TGF-β contributes
to enhanced ECM deposition in skeletal muscle.
7. STAT3 Signaling Contributes to Muscle Wasting in Cancer Cachexia
The role of STAT3 in muscle function has been reviewed [133,134]. It is reported that STAT3
contributes to muscle wasting in PDX animal models, as constitutively active STAT3 induces
muscle fiber atrophy and exacerbates wasting in cancer cachexia [135,136] in an NF-kB dependent
manner [137]. Conversely, inhibition of STAT3 reduces muscle atrophy in cancer [135,136]. These
observations are consistent with STAT3 signaling negatively regulating MuSC expansion and skeletal
muscle regeneration. Pharmacological inhibition of Stat3 activity enhances MuSC proliferation
and muscle repair after injury or during diseased conditions [138,139]. Interestingly, a recent study
demonstrated that Stat3 promotes the progression of MuSCs to myogenic lineage through mitochondrial
respiration [140], indicating the involvement of mitochondria in muscle repair or muscle wasting
in disease conditions. Indeed, JAK2/STAT3 signaling improves cardiac dysfunction by normalizing
mitochondrial respiratory function in vivo and in vitro [141] through regulating reactive oxygen
species (ROS) formation [142]. Mitochondria are one of the most important sources of ROS in skeletal
muscles [143]. The role of ROS and redox signaling in muscle function and muscle regeneration has
been reviewed [143–145]. Mitochondrial STAT3 has also been implicated in modulating mitochondrial
DNA, mitochondrial transcription, and electron transport chain activity [146–150], further influencing
cell survival and metabolism [151,152].
8. NF-κB is a Critical Signaling Relay Engaged in Breast Cancer Associated Functional Limitations
NF-κB represses myogenesis [153,154] and enhances muscle atrophy in various skeletal muscle
diseases [155–158]. Activation of NF-κB in response to TNF-αblocks muscle differentiation by enhancing
the degradation of the skeletal muscle-specific transcription factor MyoD [154,159]. Apart from TNF-α,
increased TGF-β levels in circulation of breast cancer patients [160] can activate TAK1 [161,162], which
phosphorylates IKK2 as well as NIK [163,164] and inhibits myogenesis by repressing the expression of
MyoD [75,165].
It is noted that the exact role of the NF-κB signaling pathway depends on the state of the skeletal
muscle disease and the nature of the disease. For instance, normal skeletal muscles have lower NF-κB
activity with different transcriptional profiles compared to stressed muscles. During the late-stage of
muscle differentiation, NF-κB acts as a negative regulator of differentiation through the transcriptional
repressor YinYang1 [166]. During skeletal muscle atrophy, NF-κB induces murine ring finger-1 [155],
an E3 ubiquitin ligase known to be involved in multiple models of skeletal muscle atrophy [167]. NF-κB
represses MyoD by inducing its negative regulator PAX7 [50]. Recent studies have demonstrated that
myostatin, another protein induced by NF-κB, represses miR-486 expression and inhibitors of this
molecule can overcome aging-associated sarcopenia [87,168]. By contrast, miR-486 increases MyoD and
its own expression by repressing Pax7 [169]. Furthermore, miR-486 itself controls NF-κB [86]. Mmp-9
regulates NF-κB activity, which further modulates Mmp-9 expression in skeletal muscles. NF-κB
mediated induction of nitric oxide has been reported recently [170]. Therefore, there is an intricate
signaling network with feed-forward and feedback loops comprising of NF-κB, PAX7, MyoD, myostatin,
miR-486, and MMP-9 that regulate skeletal muscle homeostasis, which is disrupted in cancer (Figure 1).
In preclinical studies, activation of NF-κB within muscles results in severe muscle atrophy in
mice [50,155]. Inhibition of NF-κB activity preserves muscle mass and reduces oxidative stress in
transgenic and PDX tumor-bearing mice [171,172]. In response to denervation-associated muscle
degeneration, IKK2 depletion prevents muscle atrophy, maintains fiber type, size, and strength,
increases protein synthesis, and reduces protein degradation [156]. Treatment of tumor-bearing animals
with a non-specific NF-κB inhibitor prevents tumor-associated muscle wasting via increased MyoD
expression and inhibition of ubiquitin-conjugating enzyme E214K in skeletal muscles [173]. Thus, NF-κB
and its associated signaling pathways are potential therapeutic targets to treat cancer-related muscle
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dysfunction (Figure 1). Indeed, we reported that the NF-κB inhibitor, dimethylaminoparthenolide
(DMAPT), restored skeletal muscle functions including grip strength and motion performance in
mammary tumor-bearing mice, accompanied by amelioration of few of the tumor-associated skeletal
muscle molecular defects [13].
9. Perspective and Conclusions
Although there has been recent progress in understanding functional limitations in breast cancer,
many areas may need to be further explored. The limited progress is mainly due to the perception
that breast cancer patients, compared to other cancer patients, rarely experience cachexia. However,
considering one in eight women in the United States is diagnosed with breast cancer and 25% of
breast cancer patients, particularly those with triple-negative breast cancer, experience cachexia [2,174],
additional studies are needed. Furthermore, myopenic obesity, which not only provides a misguided
outlook but also impacts chemotherapy tolerability [26,175], is common in breast cancer patients. Lean
muscle mass instead of BMI may need to be measured in breast cancer patients to ensure that there is no
muscle loss. Mechanistic insights into myopenic obesity are needed to develop therapeutic intervention.
In certain cases, adipose atrophy is also a concern as chemokines/cytokines that cause skeletal muscle
dysfunction in cancer also mediate adipose atrophy [176]. Healthy interaction between skeletal
muscle and adipocytes is essential as adipokines from adipocytes have a direct influence on myocytes,
particularly with respect to metabolic pathways. Cancer-associated changes in neuromuscular and
bone-skeletal muscle interaction are gaining attention. Recently, Baraldo and her colleagues reported
that permanent deletion of the mTORC1 gene results in instability in the neuromuscular junction,
which correlates with reduced treadmill performance [177]. Thus, it might be worthwhile to examine
neuromuscular junction structure integrity and stability in skeletal muscles of breast cancer patients
or animals with mammary tumors, as innervated skeletal muscle by tissue constructs has higher
contractile forces compared to non-innervated skeletal muscle [178]. Gut microbiome is another
upcoming area of research and it has recently been shown to affect skeletal muscle size, composition,
and function via a proposed gut–muscle axis [179,180]. Since cancer-induced cytokines/chemokines as
well as cancer treatments can affect the gut microbiome, it will be interesting to determine an association
between the gut microbiome and muscle dysfunction in breast cancer patients. Consistent with this
possibility, animals that lack a microbiota in gut have reduced muscle weight, reduced transcription of
genes in mitochondria, and reduced neurotransmitter for neuromuscular junction [181]. Since breast
cancer is not a single disease and broadly classified into five subtypes [182,183], how each subtype
affects skeletal muscle function is unknown. Whether molecular defects are different among subtypes
and disease stages of breast cancer remains unknown due to scarce clinical information and limited
translational knowledge. Therefore, clinical management of cancer-associated functional limitations
remains a great challenge for improving the life quality of cancer patients. In this regard, the majority
of the anti-cachexia drugs tested in clinical trials so far have proven ineffective in improving muscle
functional performance although a few of them had effects in increasing body weight and lean body
mass [184,185].
Overall, our review outlines recent advances in breast cancer-induced functional limitations,
highlighting the role of circulating cytokines/chemokines, microRNAs, mitochondria, ECM,
and impaired myogenesis, as depicted in Figure 1. Molecular defects outlined here, as well as advances
being made in the field of skeletal muscle biology, offer an opportunity to develop pharmacological
interventions for the treatment of functional limitations in breast cancer in the near future.
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IFN-α, β or γ Interferon alpha, beta or gamma
IKK Inhibitor of kappaB kinase
IL-1, 2, 4, 6 or 9 Interleukin 1, 2, 4, 6 or 9
IL-1RA Interleukin 1 receptor antagonist
MAPK Mitogen-activated protein kinase
MMPs Matrix metalloproteinases
MMTV Mouse mammary tumor virus
MIP2 Macrophage inflammatory protein 2
mTORC1 Mammalian target of rapamycin complex 1
MuSC Muscle stem cell
MYF5 or 6 Myogenic factor 5 or 6
MyHC Myosin heavy chain
MyoD Myoblast determination protein 1
MyoG Myogenin
NF-κB Nuclear factor-kappa B
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TGF-β Transforming growth factor beta
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TNF Tumor necrosis factor
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